Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4005MR)

This product GTTS-WQ4005MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4005MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4886MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ15541MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ6085MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7191MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ8592MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ14088MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ4978MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ13103MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-03446962
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW